Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the safety and general clinical response of desloratadine syrup in the relief of symptoms associated with perennial allergic rhinitis in Indonesian pediatric patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Desloratadine

Criteria

Inclusion Criteria:

• Children patients of both sexes aged between 2-11 years, of either gender and any race

• Unequivocal history of perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, pruritus, and lacrimation

• Minimum score for inclusion: 10

• Capable of complying with the dosing regimen

• Free of any clinically significant disease (other than allergic rhinitis)

• Antihistamine must be justified by investigating doctor

Exclusion Criteria:

• Patients with asthma who require chronic use of inhaled or systemic corticosteroids

• History of frequent, clinically significant sinusitis or chronic purulent postnasal drip

• Patients with rhinitis medicamentosa

• History of hypersensitivity to desloratadine or any of its excipients

• Doctor deems unsuitable